This paper addresses the possible effects of psychedelic drugs, notably psilocybin, on moral bio-enhancement (MBE). It will be argued that non-psychedelic substances, such as oxytocin, serotonin/serotonin reuptake inhibitors, or vasopressin, have indirect effects on M(B)E, whereas psilocybin has direct effects. Additionally, morality and happiness have been shown to operate in a circularly supportive relationship. It will be argued that psilocybin also has more direct effects on the augmentation of human happiness than non-psychedelic substances. Hence, psilocybin multiplies its effects on morality and on moral enhancement (as well as on happiness) if compared with non-psychedelic substances. Still, caution is advised if psilocybin is being used, and the correct dosage should be prescribed by an appropriate physician. Furthermore, the use of psilocybin has additional effects on moral enhancement and happiness if combined with meditation, preferably under the guidance of an experienced meditation specialist.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/bioe.13196 | DOI Listing |
Expert Opin Pharmacother
December 2024
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Introduction: Substance use disorders (SUDs) are a public health issue, with only some having FDA-approved indicated treatments and these having high attrition. Consequently, there has been interest in novel interventions (e.g.
View Article and Find Full Text PDFJ Psychoactive Drugs
November 2024
Michigan Psychedelic Center, University of Michigan, MI, Canada.
Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described the characteristics, motivations and practices of microdosers, the differences between individuals that only microdose and those that use both micro and macrodoses of psychedelics remain unexplored. In an online survey, we collected data of 6193 psychedelic consumers of which 2488 were microdosers of up to 11 different classical and atypical psychedelics.
View Article and Find Full Text PDFFront Pharmacol
June 2024
Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia (UBC), Vancouver, BC, Canada.
One of the most important developments in psychopharmacology in the past decade has been the emergence of novel treatments for mood disorders, such as psilocybin for treatment-resistant depression. Psilocybin is most commonly found in different species of mushroom; however, the literature on mushroom and fungus extracts with potential antidepressant activity extends well beyond just psilocybin-containing mushrooms, and includes both psychedelic and non-psychedelic species. In the current review, we systematically review the preclinical literature on mushroom and fungus extracts, and their effects of animal models of depression and tests of antidepressant activity.
View Article and Find Full Text PDFPsychopharmacology (Berl)
May 2024
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA.
Front Psychiatry
February 2024
SABI Mind, Calgary, AB, Canada.
Introduction: Recent research suggests that psychedelics may have potential for the treatment of various substance use disorders. However, most studies to date have been limited by small sample sizes and neglecting to include non-North American and European populations.
Methods: We conducted a global, cross-sectional online survey of adults (n = 5,268, 47.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!